Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Manchester
M.D. Anderson Cancer Center
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Southern California
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ciusss de L'Est de l'Île de Montréal
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University Hospital, Basel, Switzerland
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Stanford University
Haukeland University Hospital
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Columbia University
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Indiana University
University Hospital, Basel, Switzerland
M.D. Anderson Cancer Center
Indiana University
M.D. Anderson Cancer Center
University of Nebraska
University of Washington
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Memorial Sloan Kettering Cancer Center
The First Affiliated Hospital with Nanjing Medical University
Wuerzburg University Hospital
Chinese PLA General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
M.D. Anderson Cancer Center
Fox Chase Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Duke University
M.D. Anderson Cancer Center
University of Campinas, Brazil